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Anti-citrullinated protein autoantibodies (ACPA) in 
rheumatoid arthritis have unique properties including 
negative surface charge and sialic acid-containing Fab N-
glycosylation that does not influence CCP-binding. These 
features are introduced by somatic hypermutations, yet 
are not displayed by other highly mutated antibodies. 
Consequently, specific selection pressure(s) must drive 
ACPA+ B cells.  
 
 
 
 
Autoreactive B cells have a central role in the pathogenesis of rheumatoid arthritis (RA), and recent findings 
have proposed that anti-citrullinated protein autoantibodies (ACPA) may be directly pathogenic. Herein, we 
demonstrate the frequency of variable-region glycosylation in single-cell cloned mAbs. A total of 14 ACPA 
mAbs were evaluated for predicted N-linked glycosylation motifs in silico and compared to 452 highly-
mutated mAbs from RA patients and controls. Variable region N-linked motifs (N-X-S/T) were strikingly 
prevalent within ACPA (100%) compared to somatically hypermutated (SHM) RA bone marrow plasma cells 
(21%), and synovial plasma cells from seropositive (39%) and seronegative RA (7%). When normalized for 
SHM, ACPA still had significantly higher frequency of N-linked motifs compared to all studied mAbs 
including highly-mutated HIV broadly-neutralizing and malaria-associated mAbs. The Fab glycans of ACPA-
mAbs were highly sialylated, contributed to altered charge, but did not influence antigen binding. The analysis 
revealed evidence of unusual B-cell selection pressure and SHM-mediated decreased in surface charge and 
isoelectric point in ACPA. It is still unknown how these distinct features of anti-citrulline immunity may have 
an impact on pathogenesis. However, it is evident that they offer selective advantages for ACPA+ B cells, 
possibly also through non-antigen driven mechanisms.  
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Introduction 
Rheumatoid arthritis (RA) is a destructive 
inflammatory disease affecting 0.5-1% of the 
population and characterized by synovial 
inflammation and joint destruction (reviewed in [1]). 
Autoantibodies to proteins post-translationally 
modified by citrullination, denoted anti-citrullinated 
protein antibodies (ACPA), are found in ~65-80% of 
established RA patients and are included in the 
current ACR/EULAR RA classification criteria [2]. 
ACPA seropositive disease has a distinct 
pathogenesis compared to seronegative RA, and is 
associate with increased joint destruction and poorer 
prognosis (reviewed in [3]). Although still 
controversial, ACPA have been postulated to be 
directly involved in seropositive RA pathogenesis, 
and some ACPA can modulate disease by enhancing 
bone destruction and inducing pain in model systems 
[4, 5]. The broadening of ACPA repertoires prior to 
clinical onset of RA [6], and the relative success of B 
cell targeted treatment in certain seropositive RA 
patients [7], may further highlight a role for 
autoantibodies and B cells in RA.  
The ability of IgG Fc-glycans to modulate antibody 
effector functions is well characterized. Variations in 
the Fc-glycan profiles can augment inflammation and 
contribute to pathogenesis in autoimmune disease. 
Indeed, polyclonal ACPA-IgG exhibit decreased 
terminal galactose and sialic acid residues when 
compared to total serum IgG, consistent with a pro-
inflammatory profile [8, 9].  
In contrast to Fc-glycosylation that is present in some 
form in all IgG, Fab glycosylation is only found in 
~15-25% of serum IgG (reviewed in [10]). Although 
the consequence of Fab glycosylation remains 
undetermined, it may alter IgG functionality by 
modulating antigen binding or by extending antibody 
half-life [11-14]. Previous studies have documented 
that N-linked glycan motifs (N-glyc) can be present 
on both heavy and light chains [15, 16]. The majority 
of variable region N-glyc sites are thought to arise 
through somatic hypermutation (SHM), as only a 
small number of variable region germline alleles 
encode for amino acid sequences featuring N-glyc 
sites [17].  
Monoclonal ACPA-IgG exhibit several unique 
features including a remarkable cross-reactivity 
between different citrullinated proteins and peptides 
as well as a high rate of SHM. Herein, we further 
explore the biochemical characteristics of ACPA 
antibodies directly linked to the high level of somatic 
mutations. We report on the Fab glycosylation 
frequency and isoelectric charge properties of 
monoclonal ACPA compared to other single-cell 
derived antibodies, characterize the ACPA glycan-
profile, and discuss potential immunobiological 
implications. 
 
Results 
 
ACPA-IgG exhibit extensive N-linked glycan 
motifs  
To evaluate the frequency of N-glycosylation sites in 
different B cell populations we screened sequences 
from a range of expressed monoclonal antibodies 
derived from the blood and synovium of RA patients 
and which previously have been isolated from single 
B cells. In addition, the analysis included single cell 
BCR sequences from RA bone marrow plasma cells, 
and blood memory B cells from a healthy individual. 
For comparison, we utilized paired Ig sequences from 
the literature for antibodies with known specificities 
from HIV patients and malaria inflected patients [18, 
19]. Some RA antibodies have been published 
elsewhere but this study also included a number of 
previously unpublished clones. The investigation 
focused on 14 identified ACPA mAbs isolated from 
five different CCP-positive RA patients. Four of the 
ACPA clones were derived from synovial plasma 
cells (PC), eight from peripheral antigen-tetramer 
sorted memory B cells, and two from memory B cells 
(memB; Table 1). All ACPA were specific for 
citrullinated peptides and proteins by ELISA or 
antigen microarray assay and did not bind to arginine 
peptide versions, had no rheumatoid factor activity, 
or showed any unspecific polyreactivity to other 
control antigens. However, they were all cross-
reactive to multiple citrullinated antigens. 
Consistent with extensive SHM, ACPA clones 
displayed on average 52 mismatches compared to the 
closest predicted germline heavy chain 
rearrangement and 34 mismatches in the light chain 
sequences (Table 2). The N-glyc frequencies in 
ACPA were compared to single cell-derived mAbs 
from different B cells groups and compartments from 
RA patients and controls (Table 2, Supporting 
Information Table 1). These were pre-selected for 
higher mutation rates (>15 SHM in the VH or VL) for 
better comparisons with the highly-mutated ACPA. 
Similarly, the analyzed sequences from broadly 
neutralizing mAbs from HIV patients (HIV bnAb) 
and the Plasmodium falciparum specific memory B 
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cell sequences from malaria patients (Pf memB) were 
all highly mutated [18, 19].  
The consensus N-glyc motif (N-X-S/T) was observed 
in the variable region of all 14 ACPA (100%), 
whereby non-ACPA synovial memory B cells (syn. 
memB, 15% n=20) and bone marrow plasma cell 
(BM PC, 21% n=198) sequences derived from CCP+ 
RA patients, malaria-derived memory B cell 
sequences (Pf memB, 25%, n=103), and healthy 
memory B cell sequences (19%, n=27) were within 
the 15-25% reference range for Fab glycosylation 
(Table 2, Fig. 1A) [20, 21]. Intriguingly, circulating 
memory B cells (memB, 32%, n=25) and synovial 
plasma cells from CCP+ RA patients (syn. PC, 39% 
n=33), as well as HIV bnAb sequences (63% n=19), 
contained increased rates of variable region N-glyc 
compared to circulating memory B cells in healthy 
individuals, but still lower than that of the ACPA 
(Table 2, Fig. 1A). When adjusting for SHM rates 
(Table 1, Fig. 1A), ACPA exhibited significantly 
higher normalized N-glyc rates in paired V sequences 
compared to CCP+ synovial PC (p<0.0001), HIV 
bnAb (p=0.001), CCP+ blood memB (p<0.0001), 
synovial memB, BM PC, Pf memB, and healthy 
memB (p<0.0001, respectively). An increased 
frequency of N-glyc in ACPA was observed also 
when analyzing VH or VL regions separately (Fig 
1B, C). N-glyc in ACPA were all acquired through 
SHM (Table 1). Similarly, among the HIV bnAbs 
most N-glyc were also SHM-derived, but one HIV 
bnAb clone had a N-glyc that was featured in the 
germline sequence (Supporting Information Table 2). 
For the HIV bnAb, the light chain sequences 
contained a significantly increase in SHM-
normalized N-glyc numbers compared to other 
memB sequences (p<0.0002, Supporting Information 
Fig. 1B).  
HIV bnAbs displayed higher N-glyc frequencies in 
the light chain (42%) compared to the heavy chain 
(32%, Fig 1B, C), while the ACPA had equal 
frequencies in the heavy chain and light chain 
sequences (71%, Fig 1B, C). Notably, some ACPA 
mAbs contained up to three N-glyc motifs per chain 
(Fig. 1D). HIV bnAb also featured multiple N-glyc 
per chain, albeit at a lower rate than the ACPA. There 
was no striking difference in the location of N-glyc 
within variable region sequences (Fig. 1E), with 
ACPA N-glyc featured in both FWRs and CDRs. All 
verified ACPA clones had glycosylations sites and 
there was consequently no difference in the frequency 
of N-glyc sites in ACPA derived from synovium or 
blood B cells. Similarly, no significant difference in 
SHM-normalized N-glyc rates was observed for 
ACPA derived from synovial plasma cells compared 
to those derived from blood memory B cells 
(Supporting Information Fig. 2A). Furthermore, the 
significant differences between ACPA and control 
mAbs remained consistent when analyzing blood 
memory B cells or synovial plasma cells separately 
towards the ACPAs derived from the same 
compartment (Supporting Information Fig. 2 B and 
C). Intriguingly, synovial PC mAb isolated from 
seronegative patients exhibited a remarkably low 
frequency on N-glyc sites not only compared to 
ACPA (Table 2), but also towards synovial non-
ACPA PC mAbs isolated from seropositive 
individuals (p=0.046, Supporting Information Fig. 
2B). This suggest that although Fab glycosylation 
does not vary significantly between different RA B 
cell compartments, having a seropositive RA status 
has an impact.  
Notably, as this study focused on analyzing N-glyc 
site frequencies in the translated variable region 
amino acid sequences from single cells sequencing, 
there may consequently be differences in the 
occupancy and composition of the N-glyc sites in the 
original BCRs on the B cells.  
Fab glycans of recombinant monoclonal ACPA-
IgG are highly sialylated  
The presence of N-glyc motifs within sequences does 
not guarantee that these sites are occupied with 
glycans. To confirm whether the variable region N-
glyc motifs in the ACPA were accessible for 
glycosylation, recombinant ACPA-IgG were 
analyzed for presence of Fab glycans. Expressed 
ACPA-IgG with predicted Fab N-glyc exhibited 
increased mass compared to the control mAb on 
SDS-PAGE (Fig. 2A; 1362:01E02). A number of 
bands with different molecular weight were observed 
for certain ACPA, potentially signifying the presence 
of different glycoforms of these mAbs. Furthermore, 
PNGase F digestion (removing all N-glycans) 
resulted in a mobility shift of ACPA-IgG gamma 
chains to a comparable level to the control mAb, 
whereas Endo S digestion (removing only Fc-
glycans) produced partial reductions in IgG gamma 
chain molecular weight (Fig. 2A). This is a reliable 
and well-established method for analyzing Fc-
glycans compared to Fab-glycans without the need 
for generation of (Fab’)2 fragments. However, one 
limitation was that to ensure that functionality of the 
mAbs were maintained, the PNGase treatment was 
performed under native conditions instead of 
denaturing conditions, which could lead to only a 
partial enzyme digestion for some clones where the 
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sites are protected by the structure. Mobility shifts in 
the light chain with PNGase treatment could also be 
observed for certain clones with predicted N-glyc 
sites in the VL sequence.  
Lectin assays and mass spectrometry were utilized to 
analyze ACPA Fab glycan composition. SNA-ELISA 
suggested that the recombinant ACPA featured a high 
degree of sialylation, in contrast to control mAbs 
(Fig. 2B). SNA immunoblotting showed that certain 
ACPA mAbs contain sialylated residues on either the 
light or heavy chain (Fig. 2C), which corresponded 
with the presence of predicted N-glyc motifs (Fig. 2, 
Table 1). Importantly, non-ACPA control mAbs 
without predicted N-glyc sites in their variable region 
which were expressed in the same cell system gave 
no signal in SNA-ELISA or SNA-immunoblots, 
consistent with the low sialic acid content normally 
seen in recombinant IgG1 Fc-glycans. Curiously, 
certain ACPA-IgG expression batches had lower 
SNA reactivity but still with high ConA mannose-
reactivity compared to control IgG and a mobility 
shift between EndoS and PNGase treatment (Fig. 2A, 
B, Supporting Information Fig. 3), suggesting 
variations in the Fab glycan composition. Notably, all 
ACPA batches displayed some level of variable 
region glycosylation (Supporting Information Fig. 4). 
Together, these data demonstrate that all of the 
screened recombinant ACPA-IgG had increased size 
and/or lectin-reactivity consistent with occupied 
variable region glycosylation sites (summarized 
Table 1). To validate, we analyzed CCP2 affinity 
purified polyclonal ACPA-IgG from pooled RA 
patients using the same lectin assays, and this also 
exhibited higher levels of sialic acid content 
compared to the control IgG flow-through from the 
CCP2 column (Supporting Information Fig. 5). 
A sensitive glycopeptide profiling liquid 
chromatography mass spectrometry approach was 
used to characterize both the Fc and Fab glycan 
profiles of ACPA mAbs which confirmed the high 
sialic acid content of Fab glycans (Table 3, 
Supporting Information Table 3, Supporting 
Information Fig. 6). Additionally, ACPA Fab glycan 
compositions were observed to be distinctly different 
from Fc glycans. While the Fc glycans remained 
consistent between mAb clones and different 
recombinant production batches, a greater variation 
was detected in the Fab glycan composition. Mass 
spectrometry further revealed large intra-molecular 
variation with different composition at different N-
glyc sites for clones with multiple sites (Supporting 
Information Table 3). Notably, all expressed 
monoclonal IgG used in the current study were 
expressed at the Karolinska Institute research 
laboratory, using the same cell system and a 
standardized protocol. The Fab glycopeptide profile 
of recombinantly expressed IgG from HEK2 cell 
systems cannot be expected to have the exact same 
glycan-composition as what has been reported for 
PNGase F released Fab-glycans analyzed from 
human polyclonal ACPA-IgG [22]. Yet, many of the 
complex sialylated forms identified herein have been 
detected in RA patients [23]. In any case and more 
importantly, our results clearly indicate that the 
monoclonal IgG indeed have occupied high-sialic 
acid Fab-glycosylation sites. 
ACPA-IgG glycosylation does not influence 
antigen binding 
We speculated that the introduction of bulky glycans 
into ACPA variable regions could either contribute to 
the binding interface, or block interactions with 
antigens by steric hindrance. All of the investigated 
ACPA except the clone 1003:10A01 have high anti-
CCP3 reactivity (Fig. 3B). However, our analysis 
shows that deglycosylation of ACPA-IgG with 
PNGase F appeared to have no significant effect on 
CCP3-binding. Similar results were obtained in other 
citrulline binding assays (data not shown). One clone 
(62CFCT01E04) had an increased trend in binding 
following removal of glycans, yet this mAb appears 
to be an exception (Fig. 3B).  
To further investigate why Fab glycosylation may not 
influence antigen binding, glycan modelling was 
added to homology-based structures of the ACPA 
based on the sequence data. Whilst we cannot fully 
depict the structure of the antigen-binding surface 
without a resolved structure, it is well established that 
the antigen Ig-binding surface is generally built up by 
heavy and light chain CDR-loops. Therefore, 
surfaces further away from the loops are less likely to 
be directly involved in antigen recognition. Notably, 
the models suggested that N-glyc were positioned 
primarily outside of the predicted antigen-binding 
regions, offering a potential explanation as to why 
ACPA mAb deglycosylation did not significantly 
influence antigen binding (Fig. 3A). N-glyc were 
positioned closer to the predicted antigen binding 
region for some ACPA (1325:04C03, 
37CEPT02C04, 37CEPT01G09, 1003:10A01), yet 
these still do not appear to influence antigen binding.  
Effects of Fab glycosylation on B-cell selection 
pressures 
Since all ACPA N-glyc were introduced through 
SHM, the presence of variable region glycans may 
offer a selective advantage to ACPA+ B cells. We 
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utilized the BASELINe tool [24] to investigate the 
distribution patterns of replacement/silent mutations 
as a measurement of selection pressure, comparing 
ACPA sequences to non-ACPA RA-derived mAbs, 
using methodology previously described [25].  
Antigen-driven selection processes typically generate 
a higher level of replacement mutations compared to 
silent mutations in the CDRs, resulting in positive and 
negative selection strengths within CDRs and FWRs, 
respectively [24]. BASEline uses an algorithm that 
provides a statistical quantification of these somatic 
hypermutation patterns and presents the results as 
probability distribution graphs of selection strengths 
that can be compared between immunoglobulin 
groups. A CDR graph more to the right will indicate 
stronger positive selection in the CDRs and FRW 
graph more to the left will indicate a stronger negative 
selection pressure in the FRW.  
Intriguingly, despite the high mutation levels, ACPA 
sequences featured negative selection strengths in the 
CDRs, especially when analyzing VH sequences 
(Fig. 4A), and the negative selection strengths were 
significantly different in ACPA versus non-ACPA 
RA sequences. When comparing ACPA to non-
ACPA from different B cells compartments, the 
significant differences were primarily observed when 
comparing to synovial memory B cells and blood 
switched memory B cells from seropositive RA, 
whilst there was no significant difference compared 
to non-ACPA synovial plasma cells (Supporting 
Information Fig. 7A, B). Interestingly, also the HIV-
derived sequences also displayed negative selection 
pressure in the CDRs that were significantly different 
from control antibodies in both VH and VL sequence 
analysis (Supporting Information Fig. 8).  
When analyzing selection strengths solely based on 
glycosylation status, RA antibodies with N-glyc sites 
displayed significantly lower selection pressures in 
the heavy chain analysis compared to those without 
N-glyc motifs (Supporting Information Fig. 7C). 
Notably, the RA mAbs without glycosylation sites 
exhibit positive selection pressure in their VH CDRs, 
more in line with antigen-driven responses whereby 
the CDRs are to a larger extent responsible for the 
antigen-binding interactions (Supporting Information 
Fig. 7C).  
ACPA are more negatively charged and have a 
lower isoelectric point than control antibodies 
Structure analysis comparing the ACPA clones with 
their predicted germline-rearranged sequences 
revealed that the numerous somatic hypermutations, 
which lie outside of the potential binding region, did 
not seem to dramatically change the over all structure. 
Instead, these contribute to promoted a change in 
surface charge towards more negatively charged 
acidic surface residues. ACPA had lower theoretical 
isoelectric point (PI) than their respectively germline-
converted variable region sequences (Fig. 4B-D), 
observed in all clones bar two (37CEPT02C04 and 
37CEPT01G09). The ACPA clones also had 
significantly lower PI than non-ACPA RA synovial 
mAbs as well as HIV bnAb and Pf memB clones (Fig. 
4F). Isoelectric focusing (IEF) of CCP2-purified 
polyclonal ACPA revealed a trend for an overall shift 
towards lower PI compared to the CCP2 column 
flow-through and purified commercial polyclonal 
IgG (Fig. 4E). Even though polyclonal IgG appeared 
as a smear in IEF, as expected, this PI-shift could 
readily be detected when quantifying the color 
intensity by image analysis (Supporting Information 
Fig. 9). IEF of monoclonal antibodies correlated well 
with the theoretical PI of the antibodies, whereby the 
mAbs with lowest VH/VL PI were the ones that were 
separated at a lower pH on the gel and vice versa. The 
gels showed that the ACPA had a wide range of 
protein charge, generating PIs outside of the average 
pH 8.0-9.0 for human IgG1. Notably, the ACPA all 
had multiple isoform bands, consistent with post-
translational modification and a high content of 
negatively charged sialic acid, while the control IgG 
displayed fewer bands (Fig. 4F, Supporting 
Information Fig. 9). We also had access to a 
genetically modified version of one ACPA 
(1325:01B09-mod). In this ACPA, framework 
hypermutations (including N-glyc sites in VH and 
VL) were converted back to the closest germline 
gene, whilst the CDRs were unchanged. 
Consequently, the 1325:01B09-mod did not contain 
N-glyc sites, but had an identical theoretical PI 
compared to the original 1325:01B09 clone, and our 
analysis demonstrated that it had maintained 
citrulline binding (Supporting Information Fig. 10). 
IEF showed that the modifications resulted in a 
higher actual PI and a reduction of isoform bands 
compared to the original clone (Fig. 4E).  
From these results, we hypothesize that surface 
charge may be an important selection pressure in 
ACPA, and that negatively charged sialic acid-
containing glycans could significantly contribute to 
such a non-classical BCR selection process. 
Together, this data suggests a potential for non-
antigen driven mechanisms in the activation of 
ACPA+ B cells featuring BCR N-glyc motifs.  
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Discussion 
Our comprehensive single-cell sequence analysis 
revealed that Fab glycosylation is a prominent feature 
of ACPA+ B cells also when comparing to other 
chronic immune responses. N-glyc motifs in the 
variable region sequences of ACPA were acquired 
solely through somatic hypermutation, indicating that 
these are generated through germinal center 
responses. By comparing with antigen-specific Ig-
sequences from HIV and P. falciparum malaria, we 
concluded that N-glyc levels were significantly 
increased in ACPA following SHM rate 
normalization. Consequently, anti-citrulline 
autoreactivity had a unique glycosylation profile 
compared to the control groups. These data are in line 
with and extend previous observations of Fab 
glycosylation in polyclonal anti-citrullinated protein 
responses in RA, non-expressed BCR sequences 
from CCP-sorted cells, and a limited number of 
expressed monoclonals [22, 26, 27]. In the current 
study, we also found that ACPA Fab glycans in the 
recombinant IgG were distinctly different from the Fc 
glycans and highly sialylated, consistent with what 
has been determined for Fab glycans of serum 
polyclonal antibodies in RA patients [23, 26]. 
Notably, a subset of the investigated mAbs have 
recently been found to have substantial in vitro and in 
vivo functionality and mediate enhanced 
osteoclastogenesis, pain behavior and endotoxin-
induced arthritis [28, 29]. Therefore, the highlighted 
properties of Fab glycosylation and low charge of 
these 14 recombinant ACPA presented here within, 
may be important for future functional investigations.  
The biological significance of hypersialylated ACPA 
in RA pathogenesis is still unknown. As decreased 
sialylation of the Fc-region has been found to 
increase the osteoclast-promoting properties of 
ACPA [30], it will be of interest to determine how 
Fab-associated sialylation may modulate the 
functional properties of anti-citrulline responses. 
Furthermore, the mechanism(s) driving the 
enzymatically mediated extent, and composition, of 
Fab glycosylation in Ig remains unclear. The finding 
that polyclonal ACPA purified from RA patient 
synovial fluid featured a higher content of Fab 
glycans compared to those derived from the blood 
[26], and the reported changes to the Fc-glycan 
composition of polyclonal ACPA in patients during 
disease progression [31], suggest that inflammation 
may regulate Ig glycosylation. Factors such as IL-6 
and progesterone can modulate IgG glycosylation by 
affecting glycosyltransferases [32]. Furthermore, via 
an IL-23-Th17 cell axis, reduced expression of b-
galactoside a2,6-sialyltransferase-1 in B cells has 
been observed in an inflammatory milieu [33].  
Arguably, exactly what regulates the introduction of 
N-glyc motifs within BCR sequences and the 
selection pressures for N-glyc positive B cells 
remains even more elusive than the enzymatic 
pathways. Intriguingly, elevated Fab glycosylation 
has also been reported in vasculitis and primary 
Sjögren’s Syndrome (pSS) [25, 34], which may imply 
that this phenomenon associates with autoimmunity, 
although this has yet to be determined. Our studies 
show that N-glyc rates were increased in synovial PC 
mAbs from seropositive patients even though the 
expressed mAbs showed no reactivity to citrullinated 
antigens. This indicates that there may be 
microenvironmental influences specific for 
seropositive RA contributing to driving the Fab 
glycosylation. However, we observed no significant 
difference in the presence of Fab N-glyc motifs 
within ACPA isolated from the synovium or blood. 
The high levels of both N-glyc sites and SHM in 
ACPA suggest the potential for antigen-driven 
selection pressures in ACPA+ B cells. Yet, whether 
or not variable region glycosylation affects antigen 
binding remains unclear, as some studies report 
increases and decreases in binding [13, 35, 36], whilst 
others show no effect [37]. In our studies, we did not 
observe any effects on binding to citrullinated 
antigens. Structural modeling suggested that this may 
to some extent be explained by the observation that 
many of the N-glyc motifs are positioned outside of 
the predicted antigen-binding site. Therefore, a 
plausible explanation is that the acquisition of N-glyc 
in ACPA-Fab is mediated by non-(auto)antigen 
driven mechanisms. This is especially apparent when 
considering that the ACPA sequences showed low 
positive selection pressures in their CDRs, despite the 
extremely high levels of mutations. Furthermore, 
altered selection mechanisms have been previously 
suggested for autoimmune diseases such as RA and 
pSS [25, 38]. It is tempting to speculate that the 
selection of ACPA+ B cells could be mediated by the 
presence of Fab glycans in addition to the affinity for 
cognate antigen. Our structural analysis revealed that 
the extensive hypermutation outside of the CDRs of 
ACPA altered the charge of the variable regions 
towards more negatively charged surfaces, which 
was supported by a decreased variable region PI and 
overall charge of both polyclonal and monoclonal 
ACPA. Intriguingly, it has been reported that the 
addition of sialic acid glycans can also significantly 
decrease the PI of proteins [39] and that polyclonal 
IgG glycosylation in RA patients feature high acidic 
  7 
content [23]. Therefore, increases in Fab sialylation 
may augment a reduction of surface charge by SHM-
driven mechanisms. As changes in surface charge 
may affect antigen interactions and modulate 
physical properties such as solubility and 
thermostability, it can be hypothesized that selection 
pressure for surface properties also outside of the 
binding site may be important in chronic responses. 
These have previously been neglected, and are not 
generally considered in selection pressure models 
based on replacement and silent mutations in CDRs 
compared to frame work regions. The predominance 
of negatively charged antibodies within the APCA 
responses may also potentially significantly influence 
the functional properties of soluble ACPA-IgG as 
well as result in increased circulation half-life and 
tissue retention due to reported altered interaction 
with the neonatal Fc-receptor [40].  
The introduction of N-glyc motifs within variable 
regions has also been reported in non-Hodgkin’s 
lymphoma [16, 41]. In the lymphoma studies, 
interesting alternative selection mechanisms have 
been extensively reported, including suggested lectin 
driven interactions with the observed high level of 
BCR Fab-glycan [14, 16, 41, 42]. It is well 
established that RA patients have an increased risk of 
developing lymphoma [43], which is linked to 
disease severity and high inflammatory activity [44]. 
Patients with pSS also have a higher risk of 
lymphoma [45] and, intriguingly, infiltrating B cells 
in parotid glands in SS feature a higher frequency of 
Fab glycosylation [25]. Therefore, it would be of 
interest to determine if autoimmune B cells and 
certain lymphoma B cells are driven by similar 
selection pressures, and if variable region 
glycosylation are related to the risk of B cells 
transforming into lymphoma cells.  
A surprising finding was that HIV broadly-
neutralizing antibodies (bnAb) also feature increased 
N-glyc motifs within their variable regions. To our 
knowledge, this is the first report of variable region 
N-glyc sites in antibodies derived from chronic 
infection, although the extent of Fab glycosylation in 
expressed HIV bnAbs remains to be determined. 
Despite chronic HIV infection and chronic 
autoimmunity featuring different pathogenesis, both 
involve constant antigen exposure and long-time 
immune activation. We speculate that antigen 
variation in both RA and HIV leads to the high 
mutation rates observed in the HIV bnAb, as well as 
the broadly cross-reactive ACPA. 
In summary, our study highlights unique features of 
ACPA and explores the importance of variable region 
glycosylation in autoimmune disease and chronic 
inflammation. Given that glycosylation and negative 
surface charge are such strong characteristics of the 
anti-citrulline immune response, we hypothesize that 
acquisition of BCR N-linked glycosylation during the 
continuous evolution of autoreactive B cells may be 
important in disease pathogenesis, possibly 
mediating the breach of tolerance and/or expansion of 
autoreactive cells in the transition between latent 
autoimmunity and clinical active disease. Hence, 
these results may contribute to a better understanding 
of situations promoting Fab glycosylation, and its 
impact on the biological role of secreted ACPA and 
ACPA+ B cells. 
 
Materials and Methods 
 
Patients samples 
All patients fulfilled the 2010 ACR/EULAR 
classification criteria for RA [2], and were classified 
as ACPA seropositive or seronegative disease using 
the IgG anti-CCP2 assay. All subjects gave informed 
consent and the study was approved by local ethics 
review committees. Synovial fluid samples were 
collected when the patients required arthrocentesis 
due to local disease activity. Bone marrow was 
obtained at the time of joint-replacement surgery. 
Mononuclear cells were prepared from samples with 
Ficoll-Paque separation (GE Healthcare) and 
cryopreserved until use. 
 
Single B cell sorting and cloning 
Single B cells from different B cells populations and 
compartments were isolated as described below. All 
flow cytometry sorting was performed in accordance 
with the guidelines described in Cossarizza et al [46] 
and representative gating is shown in Supporting 
Information Fig. 11 and Fig. 12. 
RA bone marrow plasma cell derived clones:  
Single CD19+ (dim and bright) CD138+ plasma cells 
from bone marrow were sorted into 96-well PCR 
plates by flow cytometry.  
RA synovial memory B cells:  
Single CD19+ IgG+ memory B cells from synovial 
fluid were sorted by flow cytometry as previously 
described [47].  
RA synovial plasma cell derived ACPA positive and 
negative clones:  
For the isolation of single plasma cells from synovial 
fluid, the fluorescent foci method  was applied [48], 
using anti-human IgG-specific beads and FITC-
labelled anti-human IgG to identify IgG-secreting 
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cells by fluorescent microscopy [28], which were 
extracted using an Eppendorf NK micromanipulator. 
Following cloning and expression, the ACPA 
positive clones were identified (Table 2). 
RA blood memory derived ACPA negative and 
positive clones obtained by tetramer sorting:  
Single citrulline-specific B cells were sorted by flow 
cytometry from peripheral blood of RA patients using 
an antigen-tetramer system based on phycoerythrin 
(PE)-conjugated streptavidin (Prozyme) and biotin 
cit-peptides [29]. Briefly, citrullinated human 
filaggrin (cfc1-cyc) or a-enolase (CEP-1) tetramer-
specific cells were enriched using PE-MACS 
(Miltenyi Biotec) followed by flow cytometry sorting 
of CD19+ PE-tetramer+ B cells. Decoy-tetramers in 
PE-Alexa647 using arginine version of the peptides 
were utilized to remove unspecific cells. 
Recombinant mAbs were expressed and ACPA 
positive clones were identified (Table 2). Control 
CD19+IgD-CD27+ cells from the MACS flow 
through fraction was sorted as RA blood switched 
memory B cells.  
RA synovial memory derived ACPA positive clone: 
RA synovial CD27+ memory B cells were sorted 
with flow cytometry and transduced with Bcl-6 and 
Bcl-xL as previously described [49]. The transduced 
cells were sorted into wells with flow cytometry and 
cultured in the presence of CD40L and IL-21. 
Supernatants were screened for citrullinated peptide 
reactivity by ELISA and the ACPA clone 
1003:10A01 was identified [50].  
RA blood memory derived ACPA positive clone 
obtained by EBV immortalization: 
 The ACPA positive blood memory derived clone 
BCVA1 was isolated from RA PBMC using methods 
previously described [51, 52]. Briefly, CD22+ cells 
were enriched using MACS microbeads (Miltenyi) 
and subsequently sorted for IgG+ cells. The cells 
were immortalized with EBV, seeded into 384 wells, 
and cultured in the presence of 2.5 µg/ml CpG (ODN 
2006) and irradiated allogenic mononuclear cells. 
Supernatants were screened for reactivity to 
citrullinated vimentin and cDNA was generated.  
Cloning and expression of the synovial memory B 
cell-derived clones have been previously reported 
[47, 53, 54]. Immunoglobulin variable genes were 
cloned from single B cells into human heavy- and 
light-chain IgG expression vectors, after cDNA 
synthesis and PCR amplification, using established 
methods [47, 55]. All clones were subsequently 
expressed at the Karolinska institute using a 
standardized protocol and screened for cit-peptide 
reactivity by ELISA and multiplex microarray [56].  
Antibody production and purification 
Monoclonal antibodies were produced as hIgG1 by 
transient co-transfection of heavy- and light-chain 
vectors by PEI-max (Polysciences Inc.) into Expi293 
cells (Life Technologies) and affinity purified by 
Protein G Fast-Flow Sepharose (GE Healthcare). 
Antibody concentrations were determined by anti-
human IgG ELISA. IgG proteins were assessed by 
SDS-PAGE, SEC analysis for aggregation, and 
antigen-specificity ELISA.  
 
Ig gene sequence analysis 
N-glyc motifs were identified in translated sequences 
of V-(D)-J regions using the NetNGlyc1.0 server 
(www.cbs.dtu.dk/services/NetNGlyc/), which 
screens sequences for the consensus N-linked 
glycosylation motif (N-X-S/T, whereby X is any 
amino acid except proline). Ig-sequences were 
analyzed by alignment to germline sequences using 
IMGT/V-quest to confirm if N-glyc were introduced 
through SHM [17]. The BASELINe program 
(Bayesian estimation of Ag-driven selection), which 
evaluates SHM patterns in Ig sequences to generate 
quantitative visualization of selection pressures [24]. 
Two-point table formats reveal selection pressure 
comparisons between groups, using both statistically 
derived numerical values and probability distribution 
graphs.  
 
Detection of N-glycans in monoclonal IgG.  
Glycans were cleaved from 12 ACPA mAbs using 
PNGase F (NEB) or Endo S (IgGZERO, Genovis), 
followed by separation of 1 µg IgG on SDS-PAGE, 
4-12% Bis-Tris gel (Life Technologies), and staining 
with SimplyBlue™ SafeStain (Life Technologies). 
For lectin immunoblots, IgG were transferred to a 
PVDF membrane (Life Technologies), blocked with 
Carbo-Free blocking solution (Vector Laboratories) 
and glycans were detected with biotin-SNA or biotin-
ConA (Vector Laboratories) followed by anti-biotin-
HRP (Jackson ImmunoResearch) and development 
with Clarity™ Western ECL substrate (BioRad). For 
lectin-ELISAs, 96-well ½ area high binding plates 
(Corning) were coated with goat (Fab’)2 anti-human 
IgG (Fab) capture antibody (Jackson 
ImmunoResearch), blocked with Carbo-Free 
blocking solution, and incubated with mAbs in 
Carbo-Free blocking buffer. Reactivity was detected 
with biotin-SNA (2 µg/ml) or biotin-ConA (0.2 
µg/ml) and streptavidin-HRP (Jackson 
ImmunoResearch), and developed with TMB 
substrate (Biolegend). Isoelectric focusing (IEF) of 
polyclonal and monoclonal ACPA was achieved 
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using Novex pH 3-10 gels and Novex IEF buffer 
system (Life Technologies) following the 
manufacturer’s instructions with separation of 10 µg 
polyclonal IgG or 5 µg monoclonal IgG at 100V 1hr, 
200V 2hrs, and 500V 40min. Gels were fixed in 12% 
trichloroacetic acid and stained with SimplyBlue™ 
SafeStain.  
 
Antigen-binding assay 
The ability of monoclonal ACPA to bind citrullinated 
peptides was assessed by Quanta Lite CCP3 IgG 
ELISA at indicated concentrations according to the 
manufacturer’s instructions (Inova Diagnostics).  
 
Glycopeptide profiling via liquid chromatography - 
mass spectrometry analysis (LC-MS/MS) 
Mass spectrometry was performed on native or 
desilaylated or degalactosylated ACPA mAbs for an 
in-depth analysis of Fab glycosylation. IgG samples 
(15 µg/sample) were trypsin digested as previously 
described [8]. Samples were kept at 10°C and injected 
onto the chromatographic column in 1 µg aliquots. 
Glycosidase treatment was performed over night at 
37°C on trypsin digests using 2.5 mU of 1) α(2–
3,6,8,9)-Sialidase A and 2) α(2–3,6,8,9)-Sialidase A 
and β(1–3,4)-Galactosidase (ProZyme, Hayward, 
CA) dissolved in 10 µL of the corresponding X10 
buffers provided by the manufacturer. 
A nano-liquid chromatography system Ultimate 3000 
connected in-line to an Elite Orbitrap mass 
spectrometer (ThermoFisher Scientific) was used. 
Reversed phase LC-separation of the peptides was 
performed on a 50 cm long EASY spray column 
(PepMap, C18, 3 µm, 100 Å) using a gradient solvent 
system containing (A) water with 2% acetonitrile and 
0.1% formic acid and (B) acetonitrile with 2% water 
and 0.1% formic acid. The gradient was set up as 
follows: 1−30% (B) in 79 min, 31−95% (B) in 5 min, 
95% (B) for 8 min and 1% (B) for 10 min. The flow 
rate was set at 300 nL/min. The mass spectrometer 
was operating in the positive DDA mode with a 
survey mass spectrum in the range of m/z 150-2000 
with a nominal resolution of 60,000. Following each 
MS scan, top eight most abundant precursor ions 
were selected for MS/MS with collision induced 
dissociation (CID) and electron transfer dissociation 
(ETD). 
 
Glycopeptide identification and quantitation 
Fc-IgG-glycopeptide amino acid sequences and 
glycoforms were characterized as previously 
described [8, 57]. Briefly, IgG1 Fc-glycopeptides 
were identified by their characteristic retention times 
(as determined by IgG standard) and accurate 
monoisotopic masses (within <10 ppm from the 
theoretical values) of doubly and triply charged ions 
(EEQYNSTYR) as well as of triply and quadruply 
charged ions (TKPREEQYNSTYR).  
The IgG Fab glycans of monoclonal IgG were 
identified by the predicted tryptic peptides with N-
linked glycosylation sites in the heavy and light chain 
sequences. The specific Fab glycans were identified 
via accurate monoisotopic masses (within <10 ppm 
from the theoretical values), MS/MS fragmentation 
and sialidase and galactosidase treated samples 
(Supporting Information Fig. 7). 
Quantification of Fc and Fab glycopeptides and the 
corresponding unmodified peptide sequences were 
performed in a label-free manner using Quanti 
similarly to what has previously been described [8, 
58]. Glycopeptide ion abundances were integrated 
over respective chromatographic monoisotopic ion 
peaks (<10 ppm from the theoretical values) at the 
charged states described above and within a ±1.5 min 
interval around the expected retention times. 
Abundances of the Fc-glycopeptides and the light and 
heavy chain glycopeptides were normalized by their 
respective total content. A list of glycan compositions 
with corresponding suggested structures and relative 
distributions on respective glycopeptide is given in 
Supporting Information Table 3. 
 
Molecular modelling  
VH-VL structure models were generated using the 
Immunoglobulin Structure 
(PIGS) web server and the best H and L chain method 
[59], and visualized by Jmol (Jmol: an open source 
Java viewer for chemical structures in 3D, 
www.jmol.org/). The GlyProt server was utilized for 
in silico glycosylation using a basic glycan structure 
[60]. Molecular electrostatic potential (MEP) 
calculations were calculated with the PDB2PQR 
server [61] and Jmol MEP surface using RWB color 
scheme (scale -0.5, 0.5). Theoretical isoelectric 
points (PI) for VH-VL were calculated with the 
ExPaSY protparam online tool. 
 
Statistical analysis   
Statistical analysis was performed in Prism 
(GraphPad) using Kruskal-Wallis test with Dunn’s 
correction for multiple comparison or 2-sided Mann-
Whitney test for comparing continuous variables 
between groups, as appropriate. Frequencies were 
compared using Fisher’s exact test. A p<0.05 was 
considered significant. 	  
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Table 1. Details of N-linked glycosylation in monoclonal ACPA variable region sequences. 
ACPA Predicted 
N-glyc sites 
B cell type V region 
N-glyc  
N-glyc 
aa motif 
Germline 
aa motif† 
Location Confirmed glycosylation in recombinant 
IgG# 
1325:01B09 1VH, 1VL Synovial plasma cell  VH 
VL 
NGS 
NTS 
TGT 
SSS 
FWR1 
FWR1 
SDS-PAGE, lectin ELISA, MS** 
SDS-PAGE, MS** 
1325:04C03 2VH Synovial plasma cell  VH NMT 
NFS 
TMT 
SFS 
FWR3 
CDR3 
SDS-PAGE, lectin ELISA, SNA blot** 
1325:05C06 2VH Synovial plasma cell  VH 
 
NVS 
NLT 
TVS 
KLS 
FWR1 
FWR3 
SDS-PAGE, lectin ELISA, SNA blot 
1325:07E07 2VH, 1VL Synovial plasma cell  VH NDT 
NSS 
SSS 
NPS 
CDR1 
FWR3 
SDS-PAGE, lectin ELISA, MS 
   VL NLT TLT FWR3 SDS-PAGE, SNA-blot, MS 
37CEPT02C04 3VH, 1VL Blood IgG+ memory, CEP1 sorted  VH 
 
 
VL 
NVS 
NGS 
NVS 
NIS 
TVS 
GGS 
NVY 
TIS 
FWR1 
CDR1 
CDR3 
FWR1 
SDS-PAGE, lectin ELISA, SNA-blot 
 
 
SDS-PAGE, SNA-blot 
37CEPT01G09 
 
2VH Blood IgG+ memory, CEP1 sorted  VH 
VH 
NAS 
NVS 
SCY 
TVS 
CDR3 
FWR1 
SDS-PAGE, lectin ELISA, SNA-blot 
14CFCT03F09 1VL Blood IgG+ memory, CFC1 sorted  VL NFT TIT FWR1 N.D 
14CFCT02E04 1VH Blood IgG+ memory, CFC1 sorted  VH NVS TVS FWR1 N.D 
14CFCT02D09 1VL Blood IgG+ memory, CFC1 sorted  VL NRS NKN CDR1 lectin ELISA€, SNA-blot 
14CFCT02H12 1VL Blood IgG+ memory, CFC1 sorted  VL NNS KNY CDR1 lectin ELISA€, SNA-blot 
14CFCT03G09 2VH Blood IgG+ memory, CFC1 sorted  VH 
 
NVS 
NLT 
DTS 
KLS 
FWR3 
FWR3 
SDS-PAGE, lectin ELISA, SNA-blot** 
 
62CFCT01E04 2VH, 1VL Blood IgG+ memory, CFC1 sorted VH 
 
NTT 
NVT 
SSS 
SVT 
CDR1 
FWR3 
SDS-PAGE, lectin ELISA, SNA-blot 
   VL NFT DFT FWR3 SDS-PAGE, SNA-blot 
BVCA1 1VL Blood IgG+ memory VL NGS SGS FWR3 Double bands, lectin ELISA, SNA blot 
1003:10A01 1VL Synovial IgG+ memory  VL NNS 
NST 
SSS 
SST 
CDR3 
CDR3 
SDS-PAGE, lectin ELISA, SNA-blot 
 
† As determined by IMGT V-QUEST [17]. N.D. not determined, due to low recombinant expression yields 
# Recombinant human IgG1, determined by digestion with endoglycosidases (PNGase and EndoS) and separation by SDS-PAGE, and SNA blots, and/or ConA/SNA lectin ELSA and mass 
spectrometry. Notably the ELISA cannot determine if the glycosylation is localized on the heavy or light chain 
** Large batch variations were observed for sialic acid content 
 	  
  14 
Table 2. N-linked variables region glycosylation sites in ACPA compared to antibodies derived from other B-cell groups.  
VH 
SHM* 
VH 
N-glyc sites/SHM 
VL 
SHM* 
VL 
N-glyc sites/SHM 
Total paired VH+VL  
N-glyc sites/SHM 
Total frequency N-glyc positive clones 
 
 Mean Mean±SD p-value# Mean Mean±SD p-value# Mean±SD p-value# % (n/N) p-value€ OR (95% CI) 
ACPA (N=14) 52 0.027±0.025  34 0.027±0.029  0.032±0.018  100% (14/14) 
  
            Control mAb sequences            
Healthy memB (N=27) 22 0.007±0.018 0.0002 14 0.002±0.008 <0.0001 0.004±0.0097 
 
<0.0001 19% (5/27) <0.0001 118 (6.1-2313) 
HIV bnAb (N=19) 82 0.005±0.009 0.02 70 0.007±0.010 0.03 0.006±0.008 
 
0.001 63% (12/19) 0.01 17.4 (0.9-336) 
Pf memB (N=103) 29 0.009±0.020 <0.0001 19 0.005±0.016 <0.0001 0.007±0.013 <0.0001 25% (26/103) <0.0001 84.8 (4.9-1472) 
RA mAb sequences          
memB, CCP+ RA (N=25) 24 0.071±0.016 0.0009 20 0.0095±0.20 <0.0001 0.008±0.013 <0.0001 32% (8/25) 0.001 59.7 (3.2-1126) 
BM PC, CCP+ RA (N=198) 30 0.006±0.017 
 
0,01649 
 
<0.0001 22 0.003±0.014 
 
<0.0001 0.005±0.010 
 
<0.0001 21% (42/198) <0.0001 107 (6.2-1828) 
RA non-ACPA expressed syn. mAbs§           
syn. PC, CCP- RA (N=27) 22 0.004±0.015 <0.0001 16 0 <0.0001 0.002±0.007 <0.0001 7% (2/27) <0.0001 79.0 (4.2-1501) 
syn. PC, CCP+ RA (N=33) 21 0.016±0.023 0.05 15 0.003±0.012 <0.0001 0.009±0.012 <0.0001 39% (13/33) <0.0001 44 (2.4-802) 
syn. memB, CCP+ RA (N=20) 24 0.006±0.016 0.0005 9 0 <0.0001 0.003±0.008 
 
<0.0001 15% (3/20) <0.0001 145 (6.9-3045) 
 
Healthy memB: Blood memory B cell derived mAbs from a healthy individual, HIV bAb: HIV-derived broadly neutralizing antibodies; Pf memB: Plasmodium falciparum specific mAbs; mem, 
CCP+ RA: blood derived memory B cells from CCP+ RA; BM PC, CCP+ RA: bone marrow plasma cell derived mAbs from CCP+ RA; syn. PC, CCP- RA: synovium plasma cell derived 
expressed mAbs from RA; syn. PC, CCP- RA: synovium plasma cell derived expressed mAbs from CCP + RA; syn memB, CCP+ RA. synovium memory B cell derived expressed mAbs from 
CCP+ RA.  
Predicted N-linked glycosylation sites were identified in the variable regions of immunoglobulin genes from single-cell cloned B cells using the NetNGlyc1.0 server 
(www.cbs.dtu.dk/services/NetNGlyc/), searching for classical N-X-S/T sites.  
n= number of clones with variable region glycosylation site 
N= total number of clones in the B-cell group 
§ All non-ACPA synovial mAbs were expressed and extensively evaluated and showed no reactivity to citrullinated antigens. 
* All antibodies in the B cell groups included in the analysis were selected to have more than 15 SHM in the heavy chain and/or the light chain for more accurate comparison to ACPA sequences.  
# P-value compared to the ACPA group derived from Kruskal-Wallis test with adjustment for multiple comparisons. 
€ P-value compared to the ACPA group derived from Fisher’s exact test 
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Table 3. Mass spectrometry analysis determined the glycan composition of two ACPA mAbs.  
Monoclonal IgG 1325:01B09*  
  
1325:07E07§  
  
IgG region Fc (YNSTY) HC (LNCSV) LC (GNTSN) Fc (YNSTY) HC (INDTT) LC (ANLTI) 
       
Total number of identified glycopeptides (n) 21 39 48 16 33 40 
Number of identified sialylated glycopeptides (n) 2 18 25 1 5 19 
Relative abundance of sialylated glycoforms /peptide (%) 0.1% 49% 60% 0.1% 3% 63% 
 
A full list of the identified glycan compositions and relative abundances is given in Supporting Information Table 4. 
* 1325:01B09 batch C was used for analysis, previously confirmed to feature high content of sialylation (Supporting Information Fig. 4) 
§ 1325:07E07 batch B was used for analysis 
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Figure 1 Monoclonal ACPA-IgG contain significantly increased N-glyc motifs.  
Consensus N-glyc motifs (N-X-S/T) were identified in paired V chain (A) VH chain (B), and VL chain (C) sequences. 
The analysis compares RA ACPA mAbs with sequences from 27 heathy circulating memory B cells (healthy memB), 
27 synovial plasma cells from seronegative RA (CCP- syn. PC), and 25 circulating memory B cells (CCP+ RA blood 
memB), 198 bone marrow plasma cells (CCP+ RA BM PC), 33 synovial plasma cells (CCP+ RA syn. PC), and 20 
synovial memory B cells (CCP+ RA syn. memB) from seropositive RA patients. The analysis also included published 
broadly-neutralizing HIV antibodies (HIV bnAb) [18] and Plasmodium falciparum antibodies (Pf memB) [19]. All 
clones were selected to carry more than 15 somatic hypermutations (SHM) in either the VH or VL sequences. 
Glycosylation rates were depicted as the percentage of sequences containing N-glyc motifs (left panels) or N-glyc rates 
normalized for SHM (right panels). P-values were determined by Kruskal-Wallis test with adjustment for multiple 
comparisons, * p-value <0.05, ** p-value<0.01, *** p-value<0.001 **** p-value<0.0001. Mean and SD are depicted. 
D. Number of N-glyc sites per V-chain (left panel) and location of N-glyc sites within VH and VL chains (right panel) 
in the framework regions (FWRs) and complementary-determining regions (CDRs). BCR variable region sequences 
were analyzed in silico using IMGT V-quest [17] and the NetNGlyc1.0 server (www.cbs.dtu.dk/services/NetNGlyc/).   	  
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Figure 2 Deglycosylation revealed that Fab glycan motifs are occupied in monoclonal ACPA. 
 A. Coomassie blue stained SDS-PAGE of 12 recombinantly expressed monoclonal ACPA-IgG treated with PNGase F 
(cleaves all N-linked glycans) and Endo S (cleaves only Fc N-linked glycans) or left untreated, run under reducing 
conditions. Glycan compositions were determined by lectin ELISA (B) and by SNA immunoblotting detecting sialic 
acid containing glycans (C), which revealed high rates of sialylation and mannosylation for the ACPA but not the control 
mAb from RA synovial memory B cells (Control IgG(a) 1362:01E02, Control IgG(b) 1276:01G09), control IgG from 
RA plasma cell (Control IgG(c) 1276:06D06) or the commercial human IgG1 isotype control (Control IgG(d) ET901, 
Biolegend). Data shown in A, B and C are representative of three independent experiments. ELISA reactivity in B was 
analyzed in duplicates.  
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Figure 3 Fab glycosylation did not affect antigen binding.  
A. Homology-based structural predictions of ACPAs with predicted N-glyc sites revealed that Fab N-glyc sites on 
ACPA are primarily positioned outside of the predicted antigen-binding surface built up by the CDR, whereas others 
lie close to potential binding regions. Models are visualized for the VH/VL region of the mAbs as cartoons of light chain 
variable region in red and heavy chain region in blue with the light chain CDR loops highlighted in orange and heavy 
chain CDR loops in light blue. The VH/VL region are shown in a “top” view, looking down into the potential binding 
site generated by the CDR loops. Structure models were generated with PIGS online tool using best H + L model, basic 
glycan structures were added with GlyProt server and visualized with Jmol. B. The removal of glycans did not 
significantly alter ACPA binding to CCP3 by ELISA (Quanta Lite CCP3 IgG modified protocol, Inova Diagnostics). 
The mAb 1003:10A01 is not positive for CCP3 binding and therefore excluded in this assay. The recombinantly 
expressed synovial memory B cell derived clone 1362:01E02 was used as isotype control.  
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Figure 4 ACPA show distinct differences in selection pressure and surface charge compared to other antibody 
groups  
A. The predicted selection pressures were obtained for ACPA sequences compared to non-ACPA RA (synovial memory, 
synovial plasma cells and blood memory B cells from seropositive RA) using BASELINe computational tool [24], 
whereby selection pressures for the CDR and the FWR (upper left and lower right plots, respectively) and overlays 
(lower left plot) are visualized for heavy chains (left panel) and light chains (right panel). The dotted line depicts the 
row group and the solid line represents the column group. Positive selection pressures are depicted as red color and 
positive values, whereas negative selection pressures are shown as green color and negative values. The intensities of 
the colors depict the strength of the relative selection pressures. B. Theoretical isoelectric points (PI) for VH-VL of 13 
ACPA and their predicted germline rearrangement. P-value from pair t-test is presented. C. Homology-based structural 
surface predictions of four plasma cells derived ACPA and their predicted germline rearrangements showing 
electrostatic potential (MEP) surfaces. The RWB color (scale -.5, .5) shows positively charged surfaces as blue and 
negatively charged as red. The theoretical PI for the clones are depicted in (D). E. Isoelectric focusing (IEF) of human 
RA-derived IgG. The left panel shows a shift towards lower PI in IEF of polyclonal CCP2 affinity purified ACPA IgG 
(ACPA pool) compared to CCP2 column flow through (FT pool) and polyclonal IgG. The right panels show IEF of 
recombinant human monoclonal IgG1, revealing heterogeneity in PI of ACPA, low PI and multiple isoforms. Genetic 
modification of the ACPA clone 1325:01B09 to remove the two N-glyc sites in the VH and VL framework resulted in 
an increase in PI and a reduction of isoforms. The non-ACPA plasma cell derived clone 1276:06D06 and the memory 
B cells derived clone 1362:01E02 were used as controls in IEF. F. Theoretical VH-VL PI for different antibody groups 
compared to ACPA. P-values were determined by Kruskal-Wallis test with adjustment for multiple comparisons, mean 
and SD are shown for each group. 
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Supporting Information Table 1. Cloned and screened clones from single B cells from RA patients and controls.   
Patient ID Recruiting hospital Status Sex Age Source of B 
cells 
B cell subset No of 
clones* 
RA146 University Hospitals Birmingham  CCP+RA F 69 Synovial tissue non-ACPA syn. memory 4 
RA153 University Hospitals Birmingham  CCP+RA F 40 Synovial fluid non-ACPA syn. memory 2 
RABVCA Geneva University Hospital CCP+RA N/A N/A Blood  ACPA 1 
RA1003 Karolinska University Hospital CCP+RA F 67 Synovial fluid non-ACPA syn. memory 2 
      ACPA 1 
RA1276 Karolinska University Hospital CCP+RA F 68 Synovial fluid non-ACPA syn. memory 6 
      non-ACPA syn. PC  6 
RA1325 Karolinska University Hospital CCP+RA F 58 Synovial fluid non-ACPA syn. memory 2 
      non-ACPA syn. PC 25 
      ACPA 4 
RA1444 Karolinska University Hospital CCP+RA M 51 Synovial fluid non-ACPA syn. memory 4 
      non-ACPA syn. PC 2 
RA268 Karolinska University Hospital CCP+RA F 83 Bone marrow BM PC 198 
RA1362 Karolinska University Hospital CCP-RA M 66 Synovial fluid CCP neg syn. PC 27 
RA37 University of Minnesota Medical Center CCP+RA F 51 Blood blood memory 9 
      ACPA (CEP-sorted) 2 
RA14 University of Minnesota Medical Center CCP+RA  F 37 Blood blood memory 2 
      ACPA (CFC-sorted) 3 
RA62 University of Minnesota Medical Center CCP+RA F 67 Blood blood memory 14 
      ACPA (CFC-sorted) 1 
HC14 Karolinska University Hospital Control F 54 Blood healthy memory  27 
* All analyzed clones were selected to have >15 SHM in the heavy chain and/or light chain
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Supporting Information Table 2. HIV broadly neutralizing monoclonal 
antibodies containing N-linked glycosylation motifs within variable region 
sequences.   
bnAb Variable 
region 
N-glyc motif # Germline motif † Domain † References 
PG9 VL NGT TGT FWR1 [1] 
VRC01 VL NLT TFT FWR3 [2] 
VRC02 VL NLT TFT FWR3 [2] 
PGT121 VH NYS 
NLS 
NGT 
NYN 
TIS 
NGT 
FWR3 
FWR3 
FWR3 
[3] 
PGT122 VH NVS TVS FWR1 [3] 
PGT125 VH 
VL 
NVS 
NGT 
TVS 
TGT 
FWR1 
FWR1 
[3] 
PGT130 VH 
VL 
NVT 
NGT 
SVT 
TGT 
FWR3 
FWR1 
[3] 
PGT131 VH NVT SVT FWR3 [3] 
8ANC195 VH NLT AED FWR3 [4] 
3BNC117 VL NLT TFT FWR3 [4] 
3BNC60 VL NLT TFT FWR3 [4] 
NIH45-46 VL NLS TLT FWR3 [4] 
# As determined using the NetNGlyc1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/), to 
predict N-linked glycosylation motifs (N-X-S/T) within the variable region amino acid sequences of 
translated Ig genes. 
†As determined by IMGT V-QUEST [5].
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Supporting Information Table 3. Relative abundance and the glycan compositions identified of two ACPA mAbs 
 
Glycan   1325:01B09* 1325:07E07§ 
Suggested 
structure# 
Composition Fc   
(YNSTY) 
HC  
(LNCSV) 
LC  
(GNTSN) 
Fc  
(YNSTY) 
HC  
(INDTT) 
LC  
(ANLTI) 
GlcNAc HexNAc[1] 0.2% 0.1% 1% 0.5% - 0.1% 
M3  HexNAc[2]Hex[3] - 0.1% - - - 0.2% 
M4  HexNAc[2]Hex[4] 0.3% - - 0.1% - - 
M5 HexNAc[2]Hex[5] 1% 1% 2% 0.3% 7% 0.6% 
M6 HexNAc[2]Hex[6] - - - - - - 
M7 HexNAc[2]Hex[7] - - - 0.1% 0.2% - 
A1  HexNAc[3]Hex[3] 1% 0.9% - 1% 0.1% 2% 
A2  HexNAc[4]Hex[3] 0.2% 7% - 0.2% - 14% 
A2B or A3 HexNAc[5]Hex[3] 0.5% 2% 0.2% 2% 0.3% 3% 
A4 HexNAc[6]Hex[3] - - 0.2% - 0.5% 0.3% 
FGlcNAc dHex[1]HexNAc[1] - - 0.3% 0.1% - - 
FM3  dHex[1]HexNAc[2]Hex[3] - - 0.2% - 0.6% - 
FM6 dHex[1]HexNAc[2]Hex[6] - - - - 0.1% - 
FM7 dHex[1]HexNAc[2]Hex[7] - - 0.2% - - - 
FM9 dHex[1]HexNAc[2]Hex[9] - - 0.2% - 0.8% - 
FM10 dHex[1]HexNAc[2]Hex[10] - - 0.1% - 0.1% - 
FA1 dHex[1]HexNAc[3]Hex[3] 7% 0.4% 1% 6% 6% - 
FA2 dHex[1]HexNAc[4]Hex[3] 65% 6% 9% 73% 17% 0.2% 
FA2B or FA3 dHex[1]HexNAc[5]Hex[3] 0.2% 3% 9% 0.2% 22% 0.2% 
FA4 dHex[1]HexNAc[6]Hex[3] - 0.1% 1% - 17% - 
A1G1 HexNAc[3]Hex[4] 0.1% 0.1% - - - 1% 
M5A1 or 
M4A1G1 
HexNAc[3]Hex[5] 0.1% - - - - - 
M6A1 or 
M5A1G1 
HexNAc[3]Hex[6] 0.1% - - - 1% - 
A2G1 HexNAc[4]Hex[4] - 5% - - 0.5% 6% 
A2G2  HexNAc[4]Hex[5] - 3% - - 0.1% 2% 
A2BG1 or A3G1 HexNAc[5]Hex[4] 0.1% 4% - 0.3% - 4% 
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Glycan   1325:01B09* 1325:07E07§ 
Suggested 
structure# 
Composition Fc   
(YNSTY) 
HC  
(LNCSV) 
LC  
(GNTSN) 
Fc  
(YNSTY) 
HC  
(INDTT) 
LC  
(ANLTI) 
A2BG2 or A3G2 HexNAc[5]Hex[5] - 0.2% - - - 0.4% 
A3G3 HexNAc[5]Hex[6] - - - - 0.5% 0.1% 
A4G1 HexNAc[6]Hex[4] - 0.1% 0.1% - 0.2% 0.1% 
A4G2 HexNAc[6]Hex[5] - - - - 0.2% 0.1% 
A4G3 HexNAc[6]Hex[6] - - 0.1% - 0.1% - 
FA1G1 dHex[1]HexNAc[3]Hex[4] 1% 0.1% - 0.3% - - 
FM5A1 or 
FM4A1G1 
dHex[1]HexNAc[3]Hex[5] 0.6% - - - - - 
FM6A1 or 
FM5A1G1 
dHex[1]HexNAc[3]Hex[6] 0.2% - - - 2% - 
FM7A1 or 
FM6A1G1 
dHex[1]HexNAc[3]Hex[7] - - - - 1% - 
FM8A1 or 
FM7A1G1 
dHex[1]HexNAc[3]Hex[8] - - - - 0.1% - 
FA2G1 dHex[1]HexNAc[4]Hex[4] 21% 6% 2% 15.6% 4% 1% 
FA2G2  dHex[1]HexNAc[4]Hex[5] 1% 5% 0.3% 0.6% 3% 0.5% 
FA2BG1 or 
FA3G1 
dHex[1]HexNAc[5]Hex[4] 0.1% 8% 6% - 12% 1% 
FA2BG2  or 
FA3G2 
dHex[1]HexNAc[5]Hex[5] - 0.3% 2% - 0.5% 0.1% 
FA3G3 dHex[1]HexNAc[5]Hex[6] - - 3% - 0.0% - 
FA4G1 dHex[1]HexNAc[6]Hex[4] - - 1% - 0.7% - 
FA4G2 dHex[1]HexNAc[6]Hex[5] - - 1% - - - 
FA4G3 dHex[1]HexNAc[6]Hex[6] - - 0.3% - - - 
M4A1G1S1 HexNAc[3]Hex[5]NeuAc[1] - - 0.1% - - - 
A1G1S1  HexNAc[3]Hex[4]NeuAc[1] - - - - - 0.2% 
A2G1S1 HexNAc[4]Hex[4]NeuAc[1] - 2% 0.4% - 0.2% 7% 
A2G2S1 HexNAc[4]Hex[5]NeuAc[1] - 10% 0.3% - - 22% 
A2G2S2 HexNAc[4]Hex[5]NeuAc[2] - 4% - - - 21% 
A2BG1S1 or 
A3G1S1 
HexNAc[5]Hex[4]NeuAc[1] - 3% - - - 5% 
A2BG2S1 or 
A3G2S1 
HexNAc[5]Hex[5]NeuAc[1] - 0.2% - - - 1% 
A2BG2S2 
orA3G2S2 
HexNAc[5]Hex[5]NeuAc[2] - 0.2% 0.4% - - 0.2% 
A3G3S1 HexNAc[5]Hex[6]NeuAc[1] - 0.1% - - - 1% 
A3G3S2 HexNAc[5]Hex[6]NeuAc[2] - 0.2% - - - 1% 
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Glycan   1325:01B09* 1325:07E07§ 
Suggested 
structure# 
Composition Fc   
(YNSTY) 
HC  
(LNCSV) 
LC  
(GNTSN) 
Fc  
(YNSTY) 
HC  
(INDTT) 
LC  
(ANLTI) 
A4G1S1 HexNAc[6]Hex[4]NeuAc[1] - - 0.2% - 0.1% 0.1% 
A4G2S1 HexNAc[6]Hex[5]NeuAc[1] - 0.1% 0.1% - - 0.1% 
A4G2S2 HexNAc[6]Hex[5]NeuAc[2] - - 0.1% - - 0.1% 
A4G3S2 HexNAc[6]Hex[6]NeuAc[2] - - 1% - - - 
A4G3S3 HexNAc[6]Hex[6]NeuAc[3] - - 0.2% - - - 
FM4A1G1S1 dHex[1]HexNAc[3]Hex[5]NeuAc[1] 0.1% - - - - - 
FA2G1S1 dHex[1]HexNAc[4]Hex[4]NeuAc[1] 0.1% 2% 2% 0.1% 1.5% 0.1% 
FA2G2S1 dHex[1]HexNAc[4]Hex[5]NeuAc[1] - 14% 7% - 1.5% 3% 
FA2G2S2 dHex[1]HexNAc[4]Hex[5]NeuAc[2] - 8% 9% - 0.2% 0.3% 
FA2BG1S1 or 
FA3G1S1 
dHex[1]HexNAc[5]Hex[4]NeuAc[1] - 4% 6% - - 1% 
FA2BG2S1 or 
FA3G2S1 
dHex[1]HexNAc[5]Hex[5]NeuAc[1] - 0.3% 4% - - 0.1% 
FA2BG2S2 dHex[1]HexNAc[5]Hex[5]NeuAc[2] - - 3% - - - 
FA3G3S1 dHex[1]HexNAc[5]Hex[6]NeuAc[1] - 0.1% 7% - - 0.1% 
FA3G3S2 dHex[1]HexNAc[5]Hex[6]NeuAc[2] - 0.2% 13% - - 0.1% 
FA4G1S1 dHex[1]HexNAc[6]Hex[4]NeuAc[1] - - 0.2% - - - 
FA4G2S1 dHex[1]HexNAc[6]Hex[5]NeuAc[1] - 0.1% 1% - - - 
FA4G2S2 dHex[1]HexNAc[6]Hex[5]NeuAc[2] - - 1% - - - 
FA4G3S1 dHex[1]HexNAc[6]Hex[6]NeuAc[1] - 0.1% 0.2% - - - 
FA4G3S3 dHex[1]HexNAc[6]Hex[6]NeuAc[3] - - 1.1% - - - 
FA4G4S3 dHex[1]HexNAc[6]Hex[7]NeuAc[3] - - 1.2% - - - 
FA4G4S1 dHex[1]HexNAc[6]Hex[7]NeuAc[1] - - 0.3% - - - 
FA4G4S2 dHex[1]HexNAc[6]Hex[7]NeuAc[2] - - 0.5% - - - 
        
 
* 1325:01B09 batch C was used for analysis, previously confirmed to feature high content of sialylation (FigureS4) 
§ 1325:07E07 batch B was used for analysis 
# Nomenclature is according to 
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Supporting Information Figure 1. N-glyc motifs are significantly increased in 
HIV bnAbs. 
A. VH chain memory B cell sequences revealed no significant differences in N-glyc rate, 
whereas rates were significantly increased in HIV bnAb VL chains (B) and paired V chains 
(C) compared to the other sequences. Statistical significance regarded as p<0.05, as 
determined by Kruskal-Wallis test.    
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Supporting Information Figure 2. N-glyc motif rates of mAbs isolated from 
different anatomical locations. 
A. Comparison of sequences showed no significant difference in N-glyc rate in ACPAs 
derived from synovial plasma cell (PC) or blood memory B cell (memB) B. N-glyc rates in 
expressed mAbs derived from synovial plasma cell with no ACPA reactivity (from CCP+ RA 
or CCP- RA) compared to identified ACPAs from plasma cells. C. N-glyc rate comparison 
between randomly selected blood switched memory B cells in CCP+ RA and identified 
ACPAs isolated from circulating memory B cells. All sequences were selected to have more 
than 15 SHMs in either the heavy chain or light chain. P-values were determined by Kruskal-
Wallis or Mann-Whitney test as appropriate.  
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Supporting Information Figure 3. Lectin blot confirmed deglycosylation of ACPA-IgG.  
ConA blotting of untreated, PNGase F-digested, and EndoS-digested mAbs (1µg hIgG1) revealed reduced binding of biotinylated ConA to 
endoglycosidase-cleaved ACPA. The predicted N-glyc motif numbers in the mAbs are also shown.
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Supporting Information Figure 4. Monoclonal ACPA exhibit batch variation in 
glycosylation rates.  
Lectin-ELISA showed that 1325:04C03 (A) and 1325:01B09 (B) batches had different levels 
of sialylation, as determined as reactivity against biotinylated SNA. Means of duplicates are 
shown.
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Supporting Information Figure 5. Sialylation extent of polyclonal human ACPA 
Polyclonal serum affinity purified anti-CCP2 IgG (ACPA pool) contain a high level of 
sialylation compared to the flow through IgG from the CCP2 column (FT pool), measured by 
SNA lectin ELISA. Two independent ACPA pools were analyzed (#1 purified from 35 RA 
patients; #2 purified from 108 RA patients. Means of duplicates are show. 
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Supporting Information Figure 6. Mass spectrometry analysis of ACPA 
glycopeptides 
Merged ion chromatograms of the monoisotopic glycopeptide ions. A. Merged ion 
chromatograms of glycopeptides from 1325:07E07. Main glycopeptides from the FC region 
(EEQYNSTYR), HC region (HLHLQESGPGLVKPSETLSLTCTVSGGSINDTTYYWGWIR) 
and LC region (SEDTANLTITR) are shown. Note that the glycoforms that does not contain 
sialic acid (S0) and the forms containing one sialic acid (S1) separate according to retention 
time. Following desialylation, the S0 forms remain intact but the desialylated forms are gone 
from the chromatogram. B. Merged ion chromatograms of glycopeptides from 1325:01B09. 
Main glycopeptides from the FC region (EEQYNSTYR), LC region 
(VTIPCSGNTSNIGYNIVNWYQQVPGTAPK) and the HC region (TSETLSLNCSVSR) are 
shown. Similarly, as for 1325:07E07, the glycoforms that does not contain sialic acid (S0) 
and the forms containing one sialic acid (S1) or two sialic acids (S2) separate according to 
retention time. Following desialylation, the S0 forms remain intact but the desialylated forms 
are gone from the chromatogram.  
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Supporting Information Figure 7. Selection pressure in ACPA compared to 
non-ACPA RA derived mAbs 
Predicted selection pressures were obtained for ACPA versus different sub-groups of highly 
mutated non-ACPA, for the VH (A) and VL (B) sequences. Differences in the selection 
pressures in VH (C) or VL (D) sequences of RA-derived mAbs with or without N-glyc motifs 
were also compared. The figure shows output data from the BASELINe web tool [6]. Positive 
selection pressures are depicted as red color and positive values, whereas negative 
selection pressures are shown as green color and negative values. The graphs compare the 
distribution graphs of both groups, whereby the dotted line depicts the row group and the 
solid line represents the column group. Statistical differences were derived from binomial 
statistical tests by BASELINe, whereby the intensities of the colors depict the strength of the 
relative selection pressures. 
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Supporting Information Figure 8. Selection pressure in HIV broadly neutralizing 
mAbs compared to controls 
Predicted selection pressures were obtained for HIV broadly neutralizing antibodies (HIV 
bnAb) and circulating memory B cells from a healthy individual (Healthy memB). Selection 
pressures in the VH (left) and VL (right) regions are illustrated. The figure shows output data 
from the BASELINe web tool [6]. Positive selection pressures are depicted as red color and 
positive values, whereas negative selection pressures are shown as green color and 
negative values. Statistical differences were derived from binomial statistical tests by 
BASELINe. 
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Supporting Information Figure 9. Quantification of IgG isoforms after 
isoelectric focusing of ACPA 
 
Lane profile of protein band intensity after isoelectric focusing (IEF) were quantified using 
ImageJ software and visualized in the graphs. A. Polyclonal serum affinity purified anti-CCP2 
(ACPA pool) compared to the flow through IgG from the CCP column (FT pool) and purified 
polyclonal human IgG (Jackson ImmunoResearch). B. Comparing control IgG (plasma cell 
derived 1276:06D06 with theoretical VH/VL) with three different plasma cell derived ACPA 
IgG1 with different theoretical PI but all containing Fab glycosylations. C. Comparing the 
ACPA clone 1325:01B09 with a genetically modified version, 1325:01B09-mod, with the 
same theoretical PI but without any Fab N-glycosylation sites. Theoretical VH/VL PI and Fab 
N-glyc sites are listed in the box. The visualized pH range was approximately 10.7 to 4.2. All 
mAbs were expressed in parallel in the same system and purity was confirmed with SDS-
PAGE. IEF was achieved using Novex pH 3-10 gels following the manufacturer’s instructions 
(Thermo Fisher Scientific) and separating 10 µg polyclonal IgG or 5 µg monoclonal IgG.    
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Supporting Information Figure 10. Use of a modified ACPA variant with no N-
glyc site  
 
A genetically modified version of the ACPA clone 1325:01B09 was designed. In this clone, 
somatic hypermutations in the frame work region were converted back to the closest 
germline sequence. This included the sequences encoding for the residues in the N-glyc 
sites in VH FRW1 and VL FRW1. Structure prediction (A) reveal some differences in surface 
charge but this did not change the theoretic PI compared to the original fully SHM clone (B). 
Binding to citrullinated antigens was unaffected by the changes, as demonstrated by CCP3 
ELISA (C). Homology-based structural surface predictions were generated using PIGS web 
server and the best H and L chain method [7] and molecular electrostatic potential (MEP) 
calculations were calculated with the PDB2PQR server [8]. Structures were visualized by 
Jmol showing also electrostatic potential (MEP) surfaces. The RWB color (scale -.5, .5) 
shows positively charged surfaces as blue and negatively charged as red. The VH-VL are 
shown from a “top” view looking into the potential binding site.  
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Supporting Information Figure 11. Gating strategy for flow cytometry sorting of RA blood memory derived ACPA positive 
clones by antigen tetramer staining 
A. Pre-sort analysis of PBMC from RA patient RA37 using citrullinated a-enolase (CEP-1) tetramer. B. Post-sort analysis of decoy tetramer-
bound CD19 B cells (a total of 88 cells) examined in each channel. C. Post-sort analysis of CEP-1 tetramer-bound B cells (a total of 85 cells) 
examined in each channel.
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Supporting Information Figure 12. Gating strategy for flow cytometry sorting of 
bone marrow plasma cells from RA patients 
Plasma cells were sorted from bone marrow mononuclear cells by gating on lymphocytes 
(A), single cells (B), CD19+ CD3- CD14- B cell (C) and CD138+ CD27+ plasma cells (D).  
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